ArticleJournal of diabetes and its complications2026
Trends in prevalence and incidence of diabetic retinal disease in patients with type 1 and type 2 diabetes mellitus.
Article in Journal of diabetes and its complications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeTo assess the prevalence and incidence of diabetic retinal disease (DRD) among patients with Type 1 (T1DM) and Type 2 diabetes mellitus (T2DM).
methodsData were abstracted from patients enrolled in commercial insurance and Medicare Advantage plans. Using ICD-10 coding, the yearly prevalence and incidence of DRD in T1DM and T2DM from January 1, 2016, to June 30, 2022, were analyzed. Assessments were also made into the prevalence and incidence of vision threatening disease (VTDR), defined as having a diagnosis of diabetic macular edema (DME) or proliferative diabetic retinopathy (PDR). Odds (OR) and incidence rate ratios (IRR) were also calculated.
resultsPrevalence of DRD in both cohorts increased from 2016 (T1DM:25.1%; T2DM:11.1%) through 2021 (T1DM:34.4%; T2DM:20.7%). T1DM DRD incidence decreased from 55.1/1000py in 2016 to 39.2 in 2022, while T2DM varied from 31.6 to 38.2, ending at 35.5 in 2022. VTDR (yearly OR = 4.61-4.92), DME (OR = 2.79-2.92), and PDR (OR = 6.43-6.72) each had higher prevalences in patients with T1DM vs. T2DM across all years studied (p < 0.001 for all comparisons). A similar pattern was seen for incidence as well (T1DM VTDR IRR = 2.36-2.94; DME IRR = 2.08-2.62; PDR IRR = 2.66-3.67; p < 0.001 for all T1DM vs. T2DM comparisons).
conclusionAll forms of DRD had uniformly higher prevalence and incidence in patients with T1DM compared with those with T2DM across all years observed. The incidence of T1DM DRD decreased, approaching the rate of T2DM in 2022, suggesting a reduction in the disparity between the two groups. Prevalence of VTDR, DME, and PDR was also higher in T1DM vs. T2DM. The incidence of these disease states decreased proportionally across both cohorts, maintaining relatively stable ratios.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.